Ginna G. Laport
Publications
- Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2013; (12): 1530-8
- Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR. Biol Blood Marrow Transplant. 2012; (7): 1036-1043.e1
- Changing role of stem cell transplantation in follicular lymphoma. Hematology Am Soc Hematol Educ Program. 2012: 417-25
- Follicular lymphoma: prognostic factors, conventional therapies, and hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012; (1 Suppl): S82-91
- Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cells. Biol Blood Marrow Transplant. 2012; (1): 125-33
- Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial. Bone Marrow Transplant. 2012; (10): 1350-5
- Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood. 2012; (25): 6145-54
- Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. Bone Marrow Transplant. 2012; (4): 581-8
- Tandem transplantation for follicular lymphoma: the best of both worlds? Biol Blood Marrow Transplant. 2012; (6): 820-1
- Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011; (11): 1679-87
- Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol. 2011; (13): 1195-203
- Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response. Biol Blood Marrow Transplant. 2011; (7): 1051-7
- Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA. 2011; (17): 1874-83
- Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. Bone Marrow Transplant. 2011; (2): 192-9
- Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure. Bone Marrow Transplant. 2010; (2): 303-9
- Peripheral T-cell lymphoma: autologous hematopoietic cell transplantation as first-line therapy. Curr Opin Oncol. 2010; (5): 409-13
- Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma. Biol Blood Marrow Transplant. 2010; (8): 1145-54
- The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. Biol Blood Marrow Transplant. 2010; (4): 443-68
- TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood. 2009; (5): 1099-109
- Allogeneic hematopoietic cell transplantation for Hodgkin lymphoma: a concise review. Leuk Lymphoma. 2008; (10): 1854-9
- Controversies in lymphoma: the role of hematopoietic cell transplantation for mantle cell lymphoma and peripheral T cell lymphoma. Biol Blood Marrow Transplant. 2008; (1 Suppl 1): 100-7
- Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. Blood. 2008; (3): 903-9
- Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant. 2008; (7): 741-7
- Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant. 2008; (2): 246-55
- Mantle cell lymphoma in first complete remission. Biol Blood Marrow Transplant. 2007; (9): 1118-9
- High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2006; (7): 703-11
- The role of hematopoietic cell transplantation for follicular non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2006; (1 Suppl 1): 59-65
- CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. Exp Hematol. 2005; (3): 279-85
- Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose. Blood. 2005; (6): 2300-6
- Protective conditioning for acute graft-versus-host disease. N Engl J Med. 2005; (13): 1321-31
- Rhabdomyolysis after concomitant use of cyclosporine and simvastatin in a patient transplanted for multiple myeloma. Bone Marrow Transplant. 2005; (8): 739-40
- Multiple unrelated clonal abnormalities in host bone marrow cells after allogeneic stem cell transplantation. Leuk Res. 2004; (5): 537-40
- Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood. 2003; (6): 2004-13
- Nonmyeloablative allogeneic stem cell transplantation for acute leukemia. Curr Hematol Rep. 2003; (1): 49-56
- A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancer. Bone Marrow Transplant. 2001; (7): 677-81
- Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation. Biol Blood Marrow Transplant. 2001; (4): 230-8
- A dose escalation study of total body irradiation followed by high-dose etoposide and allogeneic blood stem cell transplantation for the treatment of advanced hematologic malignancies. Bone Marrow Transplant. 2000; (8): 807-13
- Soluble interleukin-2 receptor concentration as a biochemical indicator for acute graft-versus-host disease after allogeneic bone marrow transplantation. J Hematother Stem Cell Res. 2000; (3): 393-400
- Transplantation with low-density autologous PBSC prepared with BDS60 for women with Stage II, III and IV breast cancer. Cytotherapy. 2000; (3): 179-85
- High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: a 10-year experience. Bone Marrow Transplant. 1998; (2): 127-32
- The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Semin Oncol. 1998; (4): 503-17
- Treatment of adult acute lymphoblastic leukemia. Semin Oncol. 1997; (1): 70-82

